<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02375893</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A01643-44</org_study_id>
    <nct_id>NCT02375893</nct_id>
  </id_info>
  <brief_title>Bile Acids and Gut Microbiota as Potent Coronary Atheroma Risk Factors: a Prospective Study in Human</brief_title>
  <acronym>MABAC</acronym>
  <official_title>The Official Title is in French: Microbiote, Acides Biliaires et Athérome Coronaire (MABAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the composition of bile acids and the gut microbiota&#xD;
      comparing two populations: patients with coronary atheroma and the healthy subjects.&#xD;
&#xD;
      Our hypothesis is based on the demonstration of the anti atherogenic and anti inflammatory&#xD;
      effect of certain bile acids, and the role of the gut microbiota in the metabolic regulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherosclerosis is the main cause of cardiovascular diseases which remain the first cause of&#xD;
      death worldwide. The prevention of risk factors can reduce the development of cardiovascular&#xD;
      diseases. The final goal of our study is to find new protective or new risk factors that can&#xD;
      be modulated to reduce the incidence of cardiovascular events.&#xD;
&#xD;
      Gut microbiota and its main metabolite, the bile acids, are implicated in the metabolic&#xD;
      regulation. Some bile acids, especially the secondary bile acids, transformed from the&#xD;
      primary bile acids by the bacteria of the gut microbiota, are now demonstrated in murine&#xD;
      experimental atherosclerosis models, to be anti inflammatory and anti atherogenic molecules.&#xD;
&#xD;
      We want to compare the pool of bile acids and the composition of gut microbiota between the&#xD;
      coronary patients and the healthy subjects to identify the potential protective or&#xD;
      deleterious bacteria / bile acids.&#xD;
&#xD;
      All patients admitted for a scheduled coronary angiogram will be included, then divided into&#xD;
      two groups: coronary or healthy, based on the presence or the absence of atheroma during the&#xD;
      coronary angiogram.&#xD;
&#xD;
      Feces and blood samples, and clinical and biological data, will be collected during the&#xD;
      patient's hospitalisation. No additional exam will be performed. The blood sample will be&#xD;
      collected during the coronary angiogram or during a routine blood test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gut microbiota composition in coronary patients versus healthy subject</measure>
    <time_frame>8 months</time_frame>
    <description>Observational only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bile acids composition in coronary patients versus healthy subjects, in feces and blood samples</measure>
    <time_frame>8 months</time_frame>
    <description>Observational</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Coronary patients</arm_group_label>
    <description>Feces, blood sample, clinical and biological data. Presence (1) of coronary disease defined as the presence of atheroma during the coronary angiogram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects (2)</arm_group_label>
    <description>Feces, blood sample, clinical and biological data. Absence (2) of atheroma during the coronary angiogram</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Collecting blood and feces samples</description>
    <arm_group_label>Coronary patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Healthy subject</intervention_name>
    <description>Collecting blood and feces samples</description>
    <arm_group_label>Healthy subjects (2)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Tertiary care center: cardiology unit.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - All patients admitted for a coronary angiogram&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Statins, hypolipemic drugs, corticoids, anti HIV drugs&#xD;
&#xD;
          -  Antibiotics adminisitration in the last 3 months&#xD;
&#xD;
          -  Past of cholecystectomy&#xD;
&#xD;
          -  Hepatic disorders&#xD;
&#xD;
          -  Acute coronary syndrome&#xD;
&#xD;
          -  No agreement, Insufficiency in comprehension&#xD;
&#xD;
          -  Non fasting for at least 8 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Duboc, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Department, Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>December 15, 2015</last_update_submitted>
  <last_update_submitted_qc>December 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary disease</keyword>
  <keyword>Bile acids</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Risk factors</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

